Apigenin’s Modulation of Doxorubicin Efficacy in Breast Cancer
Molecules · 2024
DOI: 10.3390/molecules29112603 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Aleksandra Golonko und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland. Hauptthemen laut MEDLINE: Apigenin, Doxorubicin, Breast Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education, “Diamond Grant” program.
Abstract (Originalsprache)
Apigenin, a naturally derived flavonoid, is increasingly being acknowledged for its potential therapeutic applications, especially in oncology. This research explores apigenin’s capacity to modulate cancer cell viability, emphasizing its roles beyond its minimal antioxidant activity attributed to its basic molecular structure devoid of hydroxyl groups. We investigated apigenin’s effects on two breast cancer cell lines, estrogen-dependent MCF-7 and non-estrogen-dependent MDA-MB-231 cells. Our findings reveal that apigenin exerts a dose-dependent cytotoxic and anti-migratory impact on these cells. Interestingly, both apigenin and doxorubicin—a standard chemotherapeutic agent—induced lipid droplet accumulation in a dose-dependent manner in MDA-MB-231 cells. This phenomenon was absent in MCF-7 cells and not evident when doxorubicin and apigenin were used concurrently, suggesting distinct cellular responses to these treatments that imply that their synergistic effects might be mediated through mechanisms unrelated to lipid metabolism. A further chemoinformatics analysis indicated that apigenin and doxorubicin might interact primarily at the level of ATP-binding cassette (ABC) transporter proteins, with potential indirect influences from the AKT and MYC signaling pathways. These results highlight the importance of understanding the nuanced interactions between apigenin and conventional chemotherapeutic drugs, as they could lead to more effective strategies for cancer treatment. This study underscores apigenin’s potential as a modulator of cancer cell dynamics through mechanisms independent of its direct antioxidant effects, thereby contributing to the development of flavonoid-based adjunct therapies in cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.
- Department of Chemistry, Biology and Biotechnology, Bialystok University of Technology, 15-351 Bialystok, Poland.
ORCID-Profile: Adam Paszko, Renata Świsłocka, Łukasz Szczerbiński
Förderung
- Ministry of Science and Higher Education
- “Diamond Grant” program
Zitieren
APA
Golonko, A., Olichwier, A. J., Szklaruk, A., Paszko, A., Świsłocka, R., Szczerbiński, Ł., & Lewandowski, W. (2024). Apigenin’s Modulation of Doxorubicin Efficacy in Breast Cancer. Molecules. https://doi.org/10.3390/molecules29112603
Vancouver
Golonko A, Olichwier AJ, Szklaruk A, Paszko A, Świsłocka R, Szczerbiński Ł, et al. Apigenin’s Modulation of Doxorubicin Efficacy in Breast Cancer. Molecules. 2024. doi:10.3390/molecules29112603
BibTeX
@article{Golonko2024,
author = {Golonko, Aleksandra and Olichwier, Adam Jan and Szklaruk, Agata and Paszko, Adam and Świsłocka, Renata and Szczerbiński, Łukasz and Lewandowski, Włodzimierz},
title = {Apigenin’s Modulation of Doxorubicin Efficacy in Breast Cancer},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29112603}
}
EUVIMED